Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 566-573

  Lim, Howard J ^a   Masin, Dana ^a   Madden, Thomas D ^b   Bally, Marcel B ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DISTEAROYLGLYCERO 3 PHOSPHOCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; LIPOSOME; MITOXANTRONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENCAPSULATION; FEMALE; MAXIMUM ALLOWABLE CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; FEMALE; LEUKEMIA L1210; LEUKEMIA P388; LIPOSOMES; LIVER; MICE; MITOXANTRONE;

EID: 0030973505     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. BALLY, M. B., MASIN, D., NAYAR, R., CULLIS, P. R. AND MAYER, L. D.: Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother. Pharamacol. 34: 137-146, 1994.
2. BALLY, M. B., NAYAR, R., MASIN, D., HOPE, M. J., CULMS, P. R. AND MAYER, L. D.: Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta 1023: 133-139, 1990.
3. BOLOTIN, E. M., COHEN, R., BAR, L. K., EMANUEL, N., NINIO, S., LASIC, D. D. AND BARENHOLZ, Y.: Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J. Liposome Res. 4: 455-79, 1994.
4. ROMAN, N. L., MASIN, D., MAYER, L. D., CULLIS, P. R. AND BALLY, M. B.: Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 54: 2830-2833, 1994.
5. BOMAN, N. L., MAYER, L. D. AND CULLIS, P. R.: Optimization of the retention properties of vincristine in liposomal vincristine. Biochim. Biophys. Acta 1152: 253-258, 1993.
6. DURR, F. E.: Biologic and biochemical effects of mitoxantrone. Semin. Oncol. 11: 3-10, 1984.
7. FIELDING, R. M.: Liposomal drug delivery: Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin. Pharmacokinet. 21: 155-164, 1991.
8. GABIZON, A. A.: Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52: 891-896, 1992.
9. GABIZON, A. AND PAPAHADJOPOULOS, D.: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A. 85: 6949-6953, 1988.
10. HOPE, M. J., BALLY, M. B., WEBB, G. AND CULLIS, P. R.: Production of large unilamellar vesicles by a rapid extrusion procedure: Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812: 55-65, 1985.
11. HWANG, K. J.: Liposome pharmacokinetics. In Liposomes from Biophysics to Therapeutics, ed. by M. J. Ostro, pp. 109-156, Marcel Dekker, New York, 1987.
12. KIM, S.: Liposomes as carriers of cancer chemotherapy: Current status and future prospects. Drugs 46: 618-638, 1993.
13. LEWIS, R. N. A. H., MAK, N. AND MCELHANEY, R.: A differential scanning calorimetric study of the thermotropic phase behavior of model membranes composed of phosphatidylcholines containing linear saturated fatty acyl chains. Biochemistry 26: 6118-6126, 1987.
14. MADDEN, T. D., HARRIGAN, P. R., TAI, L. C. L., BALLY, M. B., MAYER, L. D., REDELMEIER, T. E., LOUGHREY, H. C., TILCOCK, C. P. S., REINSIH, L. W. AND CULLIS, P. R.: The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chem. Phys. Lipids 53: 37-46, 1990.
15. MAYER, L. D., BALLY, M. B., HOPE, M. J. AND CULLIS, P. R.: Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim. Biophys. Acta 816: 294-302, 1985.
16. MAYER, L. D., CULLIS, P. R. AND BALLY, M. B.: The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin. J. Liposome Res. 4: 529-553, 1994.
17. MAYER, L. D., HOPE, M. J., CULLIS, P. R. AND JANOFF, A. S.: Solute distribution and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim. Biophys. Acta 817: 193-196, 1986.
18. MAYER, L. D., TAI, L. C. L., Ko, D. S. C., MASIN, D., GINSBERG, R. S., CULLIS, P. R. AND BALLY, M. B.: Influence of vesicle size, lipid composition, and drug to lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 49: 5922-5930, 1989.
19. MINOW, R. A., BENJAMIN, R. S. AND GOTTLIEB, J. A.: Adriamycin (NSC-123127) cardiomyopathy: An overview with determination of risk factors. Cancer Chemother. Rep. 6: 195-201, 1975.
20. NAGY, J. A., HERBERG, K. T., MASSK, E. M., ZIKNTARA, G. P. AND DVORAK, H. F.: Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res. 49: 5448-5458, 1989.
21. OGIHARA-UMEDA, I., SASAKI, T., TOYAMA, H., ODA, K., SENDA, M. AND NISHIGORI, H.: Rapid tumor imaging by active background reduction using biotin-bearing liposomes and avidin. Cancer Res. 54: 463-467, 1994.
22. PEREZ-SOLER, R.: Liposomes as carriers of antitumor agents: Toward a clinical reality. Cancer Treat. Rev. 16: 67-82, 1989.
23. RAJAGOPALAN, S., POLITI, P. M., SINHA, B. K. AND MEYERS, C. E.: Adriamycin-induced free radical formation in the perfused rat heart: Applications for cardiotoxicity. Cancer Res. 48: 4766-4769, 1988.
24. SCHWENDENER, R. A., FIEBIG, H. H., BERGER, M. R. AND BERGER, D. P.: Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and anti-tumor efficacy. Cancer Chemother. Pharmacol. 27: 429-439, 1991.
25. SCHWENDENER, R. A., HORBER, D. H., RENTSCH, K., HANSELER, E., PESTALOZZI, B. AND SAUTER, C.: Preclinical and clinical experience with liposome-encapsulated mitoxantrone. J. Liposome Res. 4: 605-639, 1994.
26. 3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat. FEBS Lett. 111: 104-106, 1980.
27. SUGARMAN, S. M. AND PEREZ-SOLER, R.: Liposomes in the treatment of malignancy: A clinical perspective. Crit. Rev. Oncol. Hematol. 12: 231-242, 1992.
28. UCHIYAMA, K., NAGAYASU, A., YAMAGIWA, Y., NISHIDA, T., HARASHIMA, H. AND KIWADA, H.: Effects of the size and fluidity of liposomes on their accumulation in tumors: A presumption of their interaction with tumors. Int. J. Pharmacol. 121: 195-203, 1995.
29. WEISS, R. B.: Mitoxantrone: Its development and role in clinical practice. Oncology 3: 135-140, 1989.
30. Wu, N. Z., DA, D., RUDOLL, T. L., NEEDHAM, D., WHORTON, A. R. AND DEWHIRST, M. W.: Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53: 3765-3770, 1993.